by Eric Christianson | Jul 30, 2025 | Endocrine Medication and Disease State Clinical Pearls
Ertugliflozin was first approved in 2017 for the treatment of type 2 diabetes. This medication is an SGLT2 inhibitor that prevents the resorption of glucose back into systemic circulation. It has been shown to be effective in lowering A1c and managing diabetes. In...
by Eric Christianson | Sep 20, 2023 | Endocrine Medication and Disease State Clinical Pearls
A few months back, I compared one of the newest SGLT2 inhibitors in bexagliflozin to the other agents in this class of medication. To sum up my analysis, bexagliflozin provided nothing significantly different from the other SGLT2 inhibitors. In fact, it has less...
